Clinical Evidence: What The STEP Trials Revealed
BMI Eligibility Criteria For Wegovy In The UK
Understanding BMI requirements for Wegovy is crucial before starting treatment. The MHRA has licensed Wegovy for adults with a BMI of 30 or above, or those with a BMI of 27 or higher who have weight-related comorbidities such as type 2 diabetes, high blood pressure, or sleep apnoea. This prescription-only medicine isn't suitable for cosmetic weight loss in individuals with normal BMI ranges.
The NICE guidance TA875 specifically recommends Wegovy alongside specialist weight management support for eligible patients. Your BMI calculation, combined with your medical history, determines whether this GLP-1 treatment aligns with clinical guidelines. EverydayMeds' clinical assessment evaluates your BMI alongside other health factors to ensure appropriate prescribing of this once-weekly injection.
Wegovy Pricing Structure And Bundle Options At EverydayMeds
Understanding the cost structure helps patients plan their BMI-focused Wegovy journey effectively. Single pens start at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. New customers apply code FIRST40 at checkout to reach these final prices, whilst returning customers use DOSE25.
Our Getting Started bundles provide convenience for the initial titration phase. The Intro Duo (0.25mg & 0.5mg) costs £169.99, whilst the Progress Trio (0.5mg, 1mg & 1.7mg) is available for £369.99. For patients reaching maintenance, the Ultimate Stability Trio provides three months of 2.4mg supply for £649.99. All bundles include next-day cold-chain delivery and clinical oversight from our GPhC-registered team (#9012878).
STEP Trial Results: Clinical Evidence For BMI-Qualified Patients
The landmark STEP 1 trial, published by Wilding et al. in the New England Journal of Medicine (2021), demonstrated significant results for patients meeting BMI criteria. In clinical trials, patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. These results specifically applied to participants with qualifying BMI measurements.
STEP 3 incorporated intensive behavioural therapy alongside Wegovy, showing approximately 16% weight reduction in eligible participants. Crucially, STEP 5 demonstrated sustainability, with patients maintaining approximately clinically studied weight loss at the two-year mark. The SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events, particularly relevant for higher BMI patients with comorbidities.
How Wegovy Works For Different BMI Categories
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural fullness hormones regardless of starting BMI within eligible ranges. The medication works by reducing appetite and promoting satiety after smaller meals, which proves particularly beneficial for patients with higher BMI measurements who struggle with portion control. Wegovy also influences brain appetite centres, potentially reducing food cravings that contribute to weight gain. The once-weekly FlexTouch pen delivers consistent medication levels, supporting appetite regulation throughout the week. Clinical studies suggest the mechanism remains effective across different BMI ranges within the licensed indication, though individual responses vary based on adherence to dietary and exercise recommendations.
EverydayMeds Ordering Process For BMI-Eligible Patients
Accessing Wegovy through EverydayMeds begins with our comprehensive 3-minute clinical assessment, which evaluates your BMI alongside medical history and current medications. Our qualified prescribers review each application within three working days (express 24-hour service available), ensuring you meet the BMI criteria and have no contraindications. Once approved, your prescription-only medicine ships via next-day cold-chain delivery, maintaining the required 2-8°C temperature throughout transit. Our GPhC-registered pharmacy (#9012878) handles all aspects of dispensing, from clinical oversight to temperature-controlled logistics. Each delivery includes detailed administration instructions and our clinical team remains available for ongoing support throughout your treatment journey.
Storage Requirements And Practical BMI Monitoring During Treatment
Proper Wegovy storage ensures medication efficacy whilst you monitor your BMI progress throughout treatment. Store unopened pens in the fridge at 2-8°C, though they remain stable at room temperature below 30°C for up to six weeks once removed—significantly longer than competing treatments. The FlexTouch pen design simplifies weekly injections, rotating between abdomen, thigh, or upper arm sites. Dose escalation follows a mandatory schedule: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg maintenance from week 17. Regular BMI monitoring helps track progress, though weight loss typically becomes apparent after reaching higher doses. Never skip dose increases as this may compromise treatment effectiveness and increase side effect risks.
UK-Specific BMI Considerations And Regional Weight Management Support
The UK's approach to BMI thresholds for Wegovy reflects our healthcare system's emphasis on evidence-based prescribing and cost-effectiveness. NHS weight management services often complement private Wegovy treatment, providing dietary counselling and exercise programmes that enhance results. Many UK patients find combining EverydayMeds' convenient Wegovy access with local authority wellness programmes maximises their investment.
Regional variations in BMI-related health risks across the UK influence treatment approaches. Scottish and Northern Irish patients may access different support services compared to those in England and Wales. EverydayMeds serves all UK regions equally, ensuring consistent access to this prescription-only medicine regardless of postcode. Our clinical team understands regional healthcare landscapes and can signpost additional support services that complement your Wegovy treatment journey.
Taking Action: BMI Assessment And Wegovy Access Today
Ready to discover whether your BMI qualifies you for Wegovy treatment? EverydayMeds streamlines the entire process from initial assessment through ongoing prescription management. Complete our clinical questionnaire, receive prescriber approval, and begin your treatment with confidence in our GPhC-registered service. New customers use code FIRST40 whilst returning customers apply DOSE25 at checkout to access our competitive pricing structure. Visit https://everydaymeds.co.uk/collections/wegovy to begin your assessment today. Our clinical team provides expert guidance every step of the way, ensuring safe and effective treatment tailored to your individual BMI profile and health circumstances.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
